文献速递肝病

综述:GLP-1受体激动剂及胰高血糖素/GIP/GLP-1受体双重或三重激动剂的作用机制与MASLD新兴治疗格局

Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.
PubMed 文献 · Aliment Pharmacol Ther · 2025-05-13

本综述聚焦代谢功能障碍相关脂肪性肝病(MASLD),汇总GLP-1受体激动剂及胰高血糖素/GIP/GLP-1受体双重或三重激动剂治疗代谢功能障碍相关脂肪性肝炎(MASH)的作用。仅纳入以肝组织学为终点的临床试验,显示基于GLP-1受体激动的药物可改善疾病活动度,替尔泊肽与survodutide显示减少纤维化的潜在临床获益。

要点

  • 基于GLP-1受体激动的药物在2期MASH试验中可改善疾病活动度。
  • 替尔泊肽与survodutide显示减少纤维化的潜在临床获益。
  • 胃肠道不良反应多为轻至中度,可能限制治疗依从性。

核心结论

  • GLP-1受体激动剂单用或联合GIP和/或胰高血糖素受体激动剂是治疗MASLD/MASH有前景且有效的药物疗法。
  • 仍需更大规模、更长疗程的临床试验进一步评估GIP受体与胰高血糖素受体激动的疗效与安全性。

研究设计与样本

  • 本综述为综合性综述,仅纳入以肝组织学评估终点的临床试验以评价疗效。

主要发现

  • MASH的2期临床试验近期证据显示,基于GLP-1受体激动的药物可有效改善疾病活动度。
  • 替尔泊肽与survodutide显示减少纤维化的潜在临床获益。
  • 其他心脏代谢获益包括体重下降及血糖控制和血脂谱改善。
  • 胃肠道不良反应可能限制治疗依从性,但严重程度一般属轻至中度。
  • 司美格鲁肽3期试验的中期分析证实其改善脂肪性肝炎的疗效,并显示改善纤维化的潜力。

局限性

  • 仍需更大规模、更长疗程的临床试验进一步评估GIP受体与胰高血糖素受体激动的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is primarily managed through diet and lifestyle modifications. However, these behavioural interventions alone may not achieve disease regression or remission, and maintaining long-term adherence is challenging. Incretin mimetics and other gastrointestinal hormones targeting the pleiotropic pathophysiological pathways underlying MASLD have now emerged as promising disease-modifying therapies. AIMS: This is a comprehensive review summarising the role of glucagon-like peptide-1 (GLP-1) receptor agonists and glucagon/glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor dual or triple agonists in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: Only clinical trials with endpoints assessed by liver histology were included for a robust evaluation of therapeutic efficacy. RESULTS: Recent evidence from phase 2 clinical trials for MASH demonstrated that pharmacological agents based on GLP-1 receptor agonism are effective in improving disease activity. Additionally, tirzepatide and survodutide showed potential clinical benefits in reducing fibrosis. Other cardiometabolic benefits observed include weight loss and improvements in glycaemic control and lipid profile. Adherence to treatment may be limited by gastrointestinal side effects, though they were found to be generally mild to moderate in severity. An interim analysis of the semaglutide phase 3 trial confirmed its efficacy in improving steatohepatitis and demonstrated its potential to improve fibrosis. CONCLUSIONS: GLP-1 receptor agonists, alone or in combination with GIP and/or glucagon receptor agonists, represent promising, effective pharmacotherapies for the treatment of MASLD/MASH. Larger and longer-duration clinical trials are needed to further evaluate the efficacy and safety of GIP receptor and glucagon receptor agonism.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Zafer M, Tavaglione F, Romero-Gómez M, et al. Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Aliment Pharmacol Ther. 2025. PMID: 40364529. doi:10.1111/apt.70196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。